Condition: Prostate Cancer · Castrate Resistant Prostate Cancer · BRCA Mutation · Sponsor: Santa Chiara Hospital
This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.
This description comes directly from the study's public registry record.
Orazio Caffo, MD · +390461902478 · orazio.caffo@apss.tn.it
Always discuss trial participation with your own doctor first.
| Sabrina Rossetti | Naples, Italy | Recruiting |
| Orazio Caffo | Trento, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06783127